Are Opioids Needed: A Double-Blinded, Randomized Controlled Trial and Examination of Predictors of Opioid Use Following ACL Reconstruction
Phase: PHASE4
Conditions: Anterior Cruciate Ligament Rupture
Sponsor: Emory University

Title: Are Opioids Needed? A Double-Blinded, Randomized 
Controlled Trial and Examination of Predictors of Opioid Use 
Following ACL Reconstruction 
NCT# NCT04285853
Date: 04/04/2022

Emory IRB Version 05/21/20
1
Emory IRB Biomedical Protocol Outline
For Investigator-Initiated Studies
1. Title Page:
Are Opioids Needed? A Double-Blinded, Randomized Controlled Trial and 
Examination of Predictors of Opioid Use Following ACL Reconstruction 
Short title: Are Opioids Needed?
Principal Investigator: 
John Xerogeanes, MD, Professor, Chief of Sports Medicine, Department of 
Orthopaedics 
Co-Investigators: 
Michael Gottschalk, MD, Assistant Professor Hand and Upper Extremity, 
Director of Clinical Research Emory, Department of Orthopaedics
Heather Samady, MD, Assistant Professor, Chief of Anesthesia, Department of 
Anesthesiology
Jennifer Hunnicutt, PhD, ATC, Postdoctoral Research Fellow, Department of 
Orthopaedics 
Sponsor: Orthopaedic Research and Education Foundation
Protocol version number and version date: Version 7; 04/04/2022
2. External (non-Emory) Collaborators (if applicable): n/a

Emory IRB Version 05/21/20
2
3. Precis/Abstract:
As the public health sector continues to confront the opioid epidemic, orthopaedic 
surgeons must revisit pain management protocols to reduce unnecessary opioid 
prescriptions. The long-term goal is to reduce opioid use and residual opioids in 
circulation. The purposes are to 1) conduct a double-blinded randomized controlled 
trial to determine the effectiveness of opioid versus non-opioid medications on post-
surgical pain, and 2) examine predictors of opioid usage in individuals following 
ACL reconstruction. Patients will use an innovative Smartphone application to track 
pain and medication usage. Additionally, patients will complete quality of life and 
pain catastrophizing questionnaires, as well as undergo pain threshold testing, to be 
used in a model to determine predictors of greater post-surgical opioid use. This study 
will provide information on non-opioid alternatives and specific predictors of post-
surgical opioid use that can be used to develop prescribing protocols. These findings 
will help orthopaedic surgeons make informed decisions when tailoring 
individualized prescriptions for patients following ACL reconstruction. Importantly, 
findings will be readily translatable into research to reduce opioid use in other 
orthopaedic surgical cohorts as well. Our ultimate goal is to lessen the burden of the 
opioid epidemic on not only our orthopaedic patients, but also society, by minimizing 
the number of opioids left in circulation.
4. Introduction and Background:
The opioid epidemic continues to cause great morbidity and mortality across the 
United States. An estimated 2.4 million people in the US meet the criteria for severe 
opioid use disorder.13 Since 2013, opioid overdose-related deaths have surpassed 
death counts from motor vehicle accidents,10 making opioid overuse the largest single 
cause of preventable death. Of all of the medical specialties, orthopaedic surgery is 
commonly implicated as a contributor to opioid over-prescription, and orthopaedic 
surgeons are ranked third highest prescribers among physicians in the US.6 As the 
public health sector continues to confront the massive opioid epidemic, orthopaedic 
surgeons must revisit post-operative pain management protocols in addressing the 
critical need to reduce unnecessary and potentially irresponsible opioid prescription 
use.
Our long-term goal is to reduce opioid use and residual opioids in circulation, while 
maximizing pain management for patients undergoing orthopaedic procedures. As a 
first step toward achieving this goal, we will focus on ACL reconstruction, which 
affects 200,000 people annually in the US. Given the young age of individuals 
undergoing ACL reconstruction, this is often their first exposure to opioid 
medications. As an estimated 2.1 million people misuse prescription opioids during 
their first exposure, these ACL patients are at major risk of prescription misuse. 
Currently, there is no consensus regarding the optimal dosing regimen. 

Emory IRB Version 05/21/20
3
Our team has generated 
compelling data on opioid use 
patterns following ACL 
reconstruction.3 A series of 264 
patients were prescribed varied 
quantities of opioids (50 tablets vs 
30 tablets). Alarmingly, a large 
number of opioids remained 
unused in both cohorts, 
demonstrating how easily excess opioids can remain in circulation. Additionally, the 
following major takeaways were learned: 1) patients adjusted their opioid use based 
on number of tablets originally prescribed; 2) patients used opioids for less days and 
reported less side effects when prescribed less; and 3) patients reported similar pain 
levels. (Table 1) Most interestingly, 16% of patients did not use opioids at all. 
These data come in support of our central hypothesis which posits that opioid use is 
not solely dependent on pain, and that other contributing factors, such as quality of 
life and pain catastrophizing (i.e., fear of pain), may be involved in the amount of 
opioids patients use. To test this hypothesis and build on preliminary data, we 
propose to conduct a double-blind, randomized controlled clinical trial, in which 
patients undergoing ACL reconstruction will be randomized to receive opioid 
(oxycodone) or non-opioid (acetaminophen) prescriptions for post-surgical pain (Aim 
1). Patients will use our innovative Smartphone application developed in our 
department to monitor pain levels, medication usage, sleep, and side effects. To 
further understand this complex relationship between pain and opioid use, we will 
study other predictors of post-surgical medication usage (i.e., quality of life).
5. Objectives:
Aim 1: To compare the effectiveness of opioid versus non-opioid medication use
following ACL reconstruction.
Hypothesis 1: Patients receiving non-opioid pain medications will have non-
inferior pain scores (i.e., numeric pain scale rating scores that are less than, or 
equal to, to that of the patients receiving opioids).
Hypothesis 2: Patients receiving non-opioid pain medications will demonstrate a 
significantly decreased use of pain medications and reported side effects 
compared to those receiving opioid pain medications. 
Aim 2: To examine predictors of pain and medication usage in individuals following 
ACL reconstruction. 
Hypotheses: We hypothesize that greater pre-surgical pain catastrophizing levels, 
decreased quality of life, and decreased pain threshold measures will be predictive 
of greater post-surgical opioid use. 
6. Study design and methods:
Aim 1 is a prospective randomized controlled trial of 100 patients undergoing ACL
reconstruction with the PI. It is important to note that aside from the randomization to
receive opioids versus no opioids (with rescue medications), all procedures are
already standard of care. Regardless, we will obtain full consent and HIPPA
authorization from patients (and parents/guardians if <18 years).
Table 1. Preliminary Data
50-Tablet
30-Tablet
p-value
Narcotic Tablets Taken
25.4 ± 13.8
15.6 ± 8.5
<0.001
Tablets Remaining 
24.6 ± 13.8
14.4 ± 8.5
<0.001
Days of Opioid Use
5.8 ± 4.6
4.5 ± 2.9
0.034
Pain Score (Day 6)
2.2 ± 1.7
2.7 ± 1.4
0.466

Emory IRB Version 05/21/20
4
Aim 2 is a prospective study of consecutive patients of PI undergoing ACL 
reconstruction. This aim is entirely covered by standard of care. For this reason, in 
addition to the large proposed sample size in Aim 2 (n=200), we are requesting oral 
consent/assent process.  
AIM 1
Design: Aim 1 will be a double-blind, randomized controlled clinical trial in patients 
undergoing ACL reconstruction. (Figure 1) All patients will receive the following as 
part of standard of care: 
1. Oral non-opioid (1000 mg acetaminophen), every 8 hours.
2. Prescription of non-opioid non-steroidal anti-inflammatory medication
(naproxen 500 mg) to be used 2x/day post-surgery.
3. Standardized multimodal intra- and post-operative protocols, including an
adductor canal peripheral nerve block.
4. Intraoperative education on post-surgical pain management. This includes
encouragement, regardless of group allocation, to not use opioids, if not
needed (pain levels <7 on Numeric Rating Scale). (We tell our patients to
consider using the opioid medication if intense pain prevents watching their
favorite show, enjoying their meals, talking with friend, etc.)
Patients will be randomized to receive opioid tablets versus placebo tablets. 
Those patients in this opioid group will receive 15 oral opioid tablets (5 
mg oxycodone) and those in placebo group will receive 15 placebo 
tablets. All patients will also receive 8 “rescue” medications: Patients who 
randomize to the non-opioid arm will receive 5mg oxycodone “rescue” 
tablets, while patients who randomize to the opioid arm will be given 
placebo “rescue” medications. The oxycodone arm will receive “rescue” 
placebo tablets to ensure consistency between groups. Importantly, 
the total number of tablets in either group is far less than the number 
of tablets that was prescribed (first 50 tablets, then 30 tablets) in our 
early studies.3 Placebo tablets (both trial and “rescue”) will be 
matched to size, shape, color, and texture of oxycodone tablets. 
These “rescue” medications are to be used only if pain is >8 (on 
Numeric Rating Scale 1-10) and does not improve within 4 hours of taking prior pain 
medication. 
Safety: We can justify these procedures because of the following information and 
safety procedures: 

Information from our pilot studies and the literature:
o
No patients in our reduced dosage pilot study required medication
beyond the 5 mg oxycodone every 4-6 hours.
o
Our preliminary data show that few patients need opioids 4-5 days
after surgery (Table 1).
o
Opioids are currently not the post-operative standard of care for ACL
surgery in Japan, Germany, Italy, and many other countries.
o
Also, this method of “rescue” medication has been successfully used
in a recent randomized controlled trial in shoulder arthroscopy,
presented by Thompson et al. at the 2019 AOSSM conference.

Safety procedures:
o
As standard of care, all patients will also stay well under the
recommended daily maximum for acetaminophen (4000mg per 24 hrs
[fda.gov]).
Randomization
Standard of Care
Placebo
Oxycodon
e
“Rescue” 
placebo
“Rescue” 
oxycodone 
Patients undergoing ACLR
Blinded
Figure 1

Emory IRB Version 05/21/20
5
o
All patients will be provided a telephone number that is the direct line
to the physician’s clinical assistant. Patients can call this number to
speak with the clinical assistant about their pain management
questions. This staff member will contact the PI, if needed. At this
point, if safety is a concern or an alternative pain management plan is
needed, the orthopaedic surgeon will be unblinded to treat patient
appropriately.
o
Additionally, patients will be contacted post-surgery by the clinical
assistant to review patient concerns.
o
All patients will attend their standard-of-care post-operative visit on
Day 3 or 4 post-surgery, where satisfaction with pain management will
be discussed. The clinical assistant will record if patients used any
“rescue” medications.
o
If safety is a concern or an alternative pain management plan is
needed, the orthopaedic surgeon will be unblinded to treat patients
appropriately. All events requiring unblinding, as well as any adverse
events, will be recorded and documented. All study staff will be
notified of these events, and appropriate reporting procedures will be
followed.
For leftover opioid disposal, we will follow the standard of care in our department, in 
which all patients are educated on proper disposal practices. These practices involve 
following FDA recommendations to bring extra opioids to a local take-back location 
or to flush extra opioids down the toilet. (Oxycodone is on FDA “flush list.”) Patients 
will also have the option to bring in their leftover opioid medications to be properly 
disposed of by study team.
Recruitment: Patients scheduled to undergo ACL reconstruction at ambulatory 
surgery center will be recruited by clinical research staff. Upon meeting inclusion 
criteria and provision of consent, patients will be prospectively enrolled. 
Randomization sequence will be created using SAS 9.4 (SAS Institute Inc., Cary, 
NC) statistical software with a 1:1 allocation using random block sizes of 2, 4, and 6. 
Non-study personnel will prepare the allocation sequence and conceal it from the 
orthopaedic surgeon in sequentially numbered, sealed, and opaque envelopes. On the 
day of surgery, only after all enrollment procedures have been completed, the non-
study personnel will select the next sealed envelope, write patient name on it, and 
then open the envelope, which will randomize the patient. Envelopes with patient 
information will be stored in a locked cabinet and will not be revealed to ortho 
surgeon (PI) during data collection. Notes will be made on patient charts requesting 
that medical personnel do not reveal group allocation to patients.
Blinding: This study will be double-blinded. Both participants and PI (orthopaedic 
surgeon) will be blinded. Placebo pills will be closely matched to oxycodone pills, so 
patients will not know to which group they are allocated. The PI will be blinded to 
group allocation. In order to keep the PI blinded, the Co-I (MBG), who practices in 
the same building, will be familiarized with each case and will sign the prescriptions. 
(See Design and Safety sections above.)
The Smartphone Application: Our team has developed a Smartphone application, 
Fuse: Post-Op Journal, for iOS (Apple) and Android (Google) devices. (Instructional 
videos are found here: http://www.acljournal.com/.) Once patients download the app, 
their smartphones alert them 3 times a day to ask them about pain levels (numeric 
rating scale 0-10), opioid and other medication usage, and side effects of medications. 
As a default, patients are alerted at 8:00am, 1:30pm, and 7:00pm, however, these 

Emory IRB Version 05/21/20
6
settings can be adjusted to within 3 hours. In the morning, the app also asks patients 
to record their satisfaction with pain management, pain locations, and hours slept. 
Patients receive a unique identifier and their responses automatically downloaded into 
an Excel sheet (Microsoft). Our team has successfully conducted research studies in 
which patients used the app.3,11 The following IRB-approved studies have used data 
from the app. (IRB#: 00092408 and IRB#: 00108695)  
Outcome Measures: Participant demographics, medical history, and relevant surgical 
information will be collected from medical records. Intraoperative and recovery room 
analgesia regimes will be recorded from patient record and compared between 
groups, similar to how we have previously reported them.9  
Pain levels: This is the primary outcome. Patients will record pain levels on 
Numeric Rating Scale 1-10 on post-operative days 0-6, as described above. 
Pain satisfaction, sleep, and side effects: Patients will rate their satisfaction (poor, 
good, excellent) with their post-op pain management. They will also record any 
side effects (constipation, nausea, euphoria, other) and hours slept each night. We 
will record number of tablets used and number of days pain medications are used, 
track patient-reported breakthrough pain, number of times patients contacted 
physician staff, and number of “rescue” tablets used. 
The following clinical outcomes will be assessed since they can affect the number of 
pain medications used: 
Quality of life will determined with the Emory QOL (equivalent to EQ-5D). EQ-
5D is a standardized measure of health status developed by the EuroQOL Group. 
(11) The patient completes the questionnaire consisting of items that ask patient to 
rate their level of problems (no problems, slight problems, moderate problems, 
severe problems, and extreme problems or unable to perform) on five dimensions: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 
AIM 2
Design: Aim 2 involves a prospective study of predictors of opioid use. 
Consecutive patients that are prescribed opioids for post-surgical pain 
management will be included in this portion of the proposed project. (Patients that 
enroll in Aim 1 will not be included in this analysis.) All data used for Aim 2 are 
part of standard of care. 
Standard of care for all enrolled patients includes standardized multimodal intra- 
and post-operative protocols including an adductor canal nerve block at the time 
of surgery, oral non-opioid (1000 mg acetaminophen) to be used every 8 hours, 
prescription of 15 tablets of oxycodone (5mg) for breakthrough pain, and 
education on pain management. Educational pamphlets are administered to all 
patients, and encouragement to not consume opioids is discussed prior to the 
patient undergoing surgery. This discussion includes education on proper 
medication usage, pain management, and disposal of leftover medications with 
patient and patient’s guardian/caretaker (if applicable).
Primary Outcome: Number of pain medication tablets used will be the primary 
outcome. As part of standard of care, patients will download the smartphone 
application to track number of pain medications used for 6 days post-surgery. 

Emory IRB Version 05/21/20
7
Predictor Variables: Patient demographics, relevant medical history, and 
relevant surgical information will be collected from medical records. Importantly, 
we will also record from medical record any previous or current history of mental 
disorders (i.e., depression, anxiety), chronic pain, and previous use/prescriptions 
of pain medications to be used in predictive model. The following outcomes will 
be physically collected pre-surgery and will also be used in the predictive model: 
Quality of life will determined with the Emory QOL (equivalent to EQ-5D), 
as described above (see Aim 1). 
Pain catastrophizing will be determined with the Pain Catastrophizing Scale 
(PCS), as described above (see Aim 1).  
Pain threshold testing will be conducted with digital pressure dolorimeters 
(Wagner Force One Model FDIX 50TM), as described above (see Aim 1). 
Risks/discomforts:
We anticipate no additional direct risks or discomfort associated with 
participation in this study other than that customary of post-ACL reconstruction. 
The known possible side effects of oxycodone include nausea, vomiting, 
constipation, lightheadedness, dizziness, or drowsiness. Close monitoring of side 
effects will be ensued with patient follow-up. A known risk of oxycodone is 
addiction. Patients will be closely monitored for signs of addiction. For Aim 1, we 
have a number of additional safety precautions in place to prevent unnecessary 
risk or discomfort (See “Safety” in Design section above) related to the pain 
medication randomization (Aim 1). The pain threshold testing has a minimal risk 
of causing discomfort. However, it is based on the patient’s own threshold/level 
of comfort. Patients will get a chance to feel the sensation on their finger first and 
see that it is more of a pressure versus painful sensation (the applicator has 1cm 
diameter and is not pointy). 
Potential benefits to subjects/science/society: 
We do not anticipate any direct benefit to participants as a result of participating. 
We do believe the findings from this study will directly benefit future patients by 
helping understanding the usage and need for pain medications post-ACL 
reconstruction. This research may help us identify better post-surgical pain 
management strategies. If the research findings are confirmed, it is possible that 
less opioids will be needed to treat post-surgical pain, thereby reducing the 
number of opioids in circulation and mitigating the opioid epidemic in 
orthopaedics. 
7. If applicable: if data/samples collected for this study will be saved/banked/archived
for future use, describe plans, who may use the material, and for what purposes (may
require a separate repository-specific IRB submission).
n/a
8. Community Participation:
n/a
9. Participant selection:

Emory IRB Version 05/21/20
8
AIM 1
Participants: Males and females, aged 14-40 years, scheduled for primary ACL 
reconstruction using quadriceps tendon autograft will be included. Adolescents 
(14-17 years) will be included because adolescents sustain ACL injuries at a 
greater rate than adults and undergo standard adult reconstructive procedures.2 In 
addition, approximately 17% of ACL reconstructions are performed on 
individuals in this age group.1 They are also more likely to be opioid naïve, and 
are thus at greater risk with their early exposure to opioids. Other inclusion 
criteria are availability of Smartphone on which patients can download the pain 
app. Exclusion Criteria involve: revision and/or contralateral ACL reconstruction 
procedures, allergies to local anesthetics, chronic pain medication use, weight <50 
kg, local infections, known coagulopathies, liver dysfunction or renal failure.
AIM 2
Participants enrolled in Aim 1 will not be included in Aim 2.
Participants: Males and females ≥14 years who are undergoing ACL 
reconstruction performed by Dr. Xerogeanes (PI) will be included. Other 
inclusion criteria are availability of a Smartphone on which patient can download 
the pain app. Patients will be excluded if they are: 1) not able to be prescribed the 
standard of care for opioids (i.e., allergies, contraindications), or 2) self-report of 
pregnant or breastfeeding.
10. Informed Consent Process:
AIM 1
Informed consent will be obtained by study personnel in a private office at the 
Emory Sports Medicine Complex or Emory Orthopaedics and Spine at Executive 
Park before any data collection occurs, or remotely (via phone or Zoom). The 
remote consent process will be assisted by the use of a REDCap E-consent 
project, which will be able to collect e-signatures of both the subject (and LAR, if 
necessary) and the member of the research team. 
If consent process is being performed via phone or Zoom, the personnel will send 
the subject or subject’s guardian a personalized email link containing a link to the 
REDCap survey that will let them view and sign the consent if they choose to 
enroll. The personnel obtaining consent will explain to each potential subject (and 
his/her legal guardian, if ≤18 years) the protocol and tests to be used in this study 
and the potential risks and benefits of participation. All study procedures will first 
be explained in common language and in the same manner during the consent 
process. Individuals (and legal guardians) will be given ample time to read over 
the consent form. Adolescents will be given time to privately discuss participation 
with their guardians, if needed. Following reading and discussion, all participants 
≥18 years will review and sign an informed consent form approved by the 
Institutional Review Board of Emory University prior to initiating any portion of 
the study. If consent is obtained remotely, subjects (or LAR of subject) will 
provide e-signature through REDCap, and will receive a copy of the consent that 
has been signed by the research team member either through encrypted email or a 
physical copy at their soonest convenience before study participation begins. For 
individuals aged ≤18 years, both assent from the individual and informed consent 

Emory IRB Version 05/21/20
9
from his/her legal guardian will be obtained prior to participation in any study-
related data collections. Assent is also available through REDCap. To prevent 
coercion and/or undue influence, consent will be obtained from study personnel 
other than the orthopedic surgeon. Should the individual (and/or legal guardian) 
wish to not participate, then all study procedures will be ceased and no data 
collection will occur. Declining to participate in this research study will have no 
negative repercussions on the medical care the individual receives as a patient of 
Emory Healthcare.
AIM 2
Using the oral consent document, verbal informed consent will be obtained by 
study personnel in a private office at the Emory Sports Medicine Complex or 
Emory Orthopaedics & Spine at Executive Park before any study procedures 
occur. We will follow similar procedures is listed in Aim 1 above. But since all 
procedures involved in Aim 2 are standard of care, as well as the large proposed 
sample size, we have requested verbal consent. 
11. Compensation for time and effort:
Participants will be compensated a total of $50 (one-time) in the form of Amazon 
gift cards upon completion of the pain survey that is provided to subjects 2 weeks 
after their surgery, and can be . A code will be emailed to participants after they 
complete the pain survey. This code can be applied to Amazon. 
12. Statistical analysis:
AIM 1
Sample Size: The sample size is based on the primary outcome, pain level. Power 
analysis was conducted based the non-inferiority nature of our research question. 
(Hypothesis 1 is confirmed if no statistical difference between groups, meaning 
non-opioid pain medication is as good as opioid medication). The minimum 
clinically significant difference for pain levels is 1.2 points on Numeric Rating 
Scale.4 Using a conservative estimate of 2 for the standard deviation of pain levels 
(SD of pain level in our pilot data = 1.9), assuming 80% power, and a one-sided 
0.05 type I error, a sample size of 35 participants per group would be required to 
test the hypothesis. To account for drop-outs, loss to follow-up, or incomplete 
pain app data, we will inflate same size in each group by 20 participants. 
Therefore, our sample size for Aim 1 will be 100 participants. As Dr. Xerogeanes 
performs >200 ACL reconstructions per year (214 ACL reconstructions in 2018), 
we should have no difficulty in obtaining required sample size.
Analyses: Using independent samples t-tests, we will compare pain levels 
(primary outcome) on post-operative days 1-6, and 2-week post-surgical visit 
(Hypothesis 1). Independent samples t-tests will also be used to compare the 
number of pain medications used and calculated total morphine equivalents. Chi 
squares tests will be used to compare the percentage of patients in each group who 
report side effects (Hypothesis 2).
AIM 2

Emory IRB Version 05/21/20
10
Sample size: A sample size of 123 participants will be needed, considering a 
moderate effect size of f2=0.15, alpha error probability of 0.05, power of 80%, 
and 11 predictor variables in the model (determined via G*Power 3.1 software). 
To maximize attrition, this number will be inflated by 5%, therefore, a sample 
size of 130 individuals will be collected. As Dr. Xerogeanes performs >200 ACL 
reconstructions per year, we foresee no issue in obtaining this sample size number 
over two-year grant period. As evidenced by sample size numbers in our previous 
investigation (n=264 over 2 year period), we have demonstrated success in 
obtaining these numbers.
Statistical Analyses: Multiple regression analyses will be used to evaluate 
predictors of post-surgical opioid use. (11 predictor variables: age; sex; diagnosis 
of mental health disorders, substance abuse, chronic pain; previous opioid usage; 
previous non-opioid pain medication usage; quality of life; pain catastrophizing; 
pain threshold scores; and pre-surgical pain levels.) First, Pearson correlation 
coefficients (r) will be used to examine the association between each of the 
predictor variables with post-surgical opioid use with a significance level of p ≤ 
0.05. The variables that are significantly correlated with opioids used will then be 
included in a step-wise regression (variable entry: p < 0.05; variable removal: p > 
0.10) to identify the primary predictors of post-surgical opioid use.
13. Data and Safety Monitoring and Reporting: Description of plan for notifying the
IRB of reportable events; whether the sponsor requires reporting above and beyond
the Emory IRB reporting requirements, and if so, a description of the requirements
and plan for meeting them; plan for periodically reviewing data for safety (if more
than minimal risk); site monitoring plan for ensuring accuracy and completeness of
documentation. See http://irb.emory.edu/documents/DSMB-DSMPGuidance.pdf for
guidance.
A number of procedures will be used to ensure the safety and welfare of study 
participants.
Oversight: The principal investigator will provide oversight of the progress and 
safety of the study. Adverse events are not anticipated, but any event that occurs 
will be documented and reported according to Emory IRB policies and 
procedures. A summary of any adverse events will be communicated to the IRB 
annually as part of the continuing review.
A clinical research coordinator dedicated to the Sports Medicine division will 
provide additional oversight and monitoring. This coordinator will monitor the 
study using the monitoring tools provided at 
http://www.irb.emory.edu/forms/clinical.html. More specifically, this involves 
ensuring the team is following regulatory responsibilities and following all 
reporting requirements. Monitoring will occur on a quarterly basis.  
Confidentiality: The identity of each participant will be protected by using a code 
number as the only identifier. The master list will be kept in locked file cabinets 
with access limited to study personnel who have completed CITI training and are 
listed on IRB.
Data Accuracy: The principal investigator will be responsible for reviewing 
protocol compliance, data collection and verification. The data will be reviewed 
qualitatively during all data collections for each participant.

Emory IRB Version 05/21/20
11
14. Confidentiality:
All records regarding participation in this study will be kept in locked file 
cabinets in the appropriate laboratories and/or offices of the PI’s research team, 
and stored on password-protected computers/servers in the offices and 
laboratories of the PI’s research team. Data will be securely stored on Emory-
approved, password-protected, and encrypted database (BOX). Only those 
investigators listed on IRB will have access to database. If outside parties help 
with statistical analysis, identifies will be stripped off first. All PHI will be 
stripped once study is completed, and no PHI will be used in presentation or 
publication of study results. The results of the study may be published for 
scientific purposes, however, individuals’ identities will not be revealed and data 
will not be traceable to any individuals in any resultant publications. The 
information gathered during this study will be kept confidential to the extent 
permitted by law.
15. References/bibliography:
1.
Dodwell ER, LaMont LE, Green DW, Pan TJ, Marx RG, Lyman S. 20 Years of
Pediatric Anterior Cruciate Ligament Reconstruction in New York State. The
American Journal of Sports Medicine. 2014;42(3):675-680.
2.
Fabricant PD, Jones KJ, Delos D, et al. Reconstruction of the anterior cruciate
ligament in the skeletally immature athlete: a review of current concepts:
AAOS exhibit selection. J Bone Joint Surg Am. 2013;95(5):e28.
3.
Farley KX, Anastasio AT, Kumar A, Premkumar A, Gottschalk MB, Xerogeanes
J. Association Between Quantity of Opioids Prescribed After Surgery or
Preoperative Opioid Use Education With Opioid Consumption. JAMA.
2019;321(24):2465-2467.
4.
Kelly AM. The minimum clinically significant difference in visual analogue
scale pain score does not differ with severity of pain. Emergency medicine
journal : EMJ. 2001;18(3):205-207.
5.
Kinser AM, Sands WA, Stone MH. Reliability and validity of a pressure
algometer. J Strength Cond Res. 2009;23(1):312-314.
6.
Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the
complexities and complications of the escalating use, abuse, and nonmedical
use of opioids. Pain Physician. 2008;11(2 Suppl):S63-88.
7.
Martin-Alguacil JL, Arroyo-Morales M, Martin-Gomez JL, Lozano-Lozano M,
Galiano-Castillo N, Cantarero-Villanueva I. Comparison of knee sonography
and pressure pain threshold after anterior cruciate ligament reconstruction
with quadriceps tendon versus hamstring tendon autografts in soccer
players. Acta Orthop Traumatol Turc. 2019.
8.
Pavlin DJ, Sullivan MJ, Freund PR, Roesen K. Catastrophizing: a risk factor for
postsurgical pain. The Clinical journal of pain. 2005;21(1):83-90.
9.
Premkumar A, Samady H, Slone H, Hash R, Karas S, Xerogeanes J. Liposomal
Bupivacaine for Pain Control After Anterior Cruciate Ligament

Emory IRB Version 05/21/20
12
Reconstruction: A Prospective, Double-Blinded, Randomized, Positive-
Controlled Trial. Am J Sports Med. 2016;44(7):1680-1686.
10.
Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved
Overdose Deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep.
2016;65(50-51):1445-1452.
11.
Runner RP, Boden SA, Godfrey WS, et al. Quadriceps Strength Deficits After a
Femoral Nerve Block Versus Adductor Canal Block for Anterior Cruciate
Ligament Reconstruction: A Prospective, Single-Blinded, Randomized Trial.
Orthop J Sports Med. 2018;6(9):2325967118797990.
12.
Sullivan MJ. The Pain Catastrophizing Scale: User Manual. 2009;
http://sullivan-painresearch.mcgill.ca/pdf/pcs/PCSManual_English.pdf.
Accessed May 1, 2019, 2019.
13.
Vashishtha D, Mittal ML, Werb D. The North American opioid epidemic:
current challenges and a call for treatment as prevention. Harm Reduct J.
2017;14(1):7.